» Articles » PMID: 16877590

The Case for Further Treatment Studies of Uncomplicated Genital Chlamydia Trachomatis Infection

Overview
Date 2006 Aug 1
PMID 16877590
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Azithromycin 1 g immediately and doxycycline 100 mg twice daily have good antimicrobial activity against Chlamydia trachomatis and treatment studies have demonstrated a >95% microbiological cure at 2-5 weeks, with antimicrobial resistance being rarely reported. Recently an 8% (95%, CI 5% to 11%) failure rate was observed in 289 women, but not in men, who had been sexually inactive after treatment. At high multiplicities of infection (load) in vitro persistence can often be demonstrated to antimicrobials-heterotypic resistance. The subsequently recovered isolates do not possess antimicrobial resistance at low loads. It is known that genital chlamydia load varies in vivo and is probably greater in women than men. In mass treatment trials of trachoma, treatment failure is associated with high chlamydia loads. It is therefore possible that women with high chlamydia loads may be at increased risk of treatment failure. Given the imminent role out of the National Chlamydia Screening Programme and the consequences of persistent chlamydial infection in women this hypothesis urgently merits further investigation.

Citing Articles

Phenotypic and Genotypic Antimicrobial Susceptibility Testing of Isolates from Patients with Persistent or Clinical Treatment Failure in Spain.

Villa L, Boga J, Otero L, Vazquez F, Milagro A, Salmeron P Antibiotics (Basel). 2023; 12(6).

PMID: 37370294 PMC: 10295289. DOI: 10.3390/antibiotics12060975.


Repeat infections with chlamydia in women may be more transcriptionally active with lower responses from some immune genes.

Huston W, Lawrence A, Wee B, Thomas M, Timms P, Vodstrcil L Front Public Health. 2022; 10:1012835.

PMID: 36299763 PMC: 9589431. DOI: 10.3389/fpubh.2022.1012835.


Elaborations on Corallopyronin A as a Novel Treatment Strategy Against Genital Chlamydial Infections.

Loeper N, Graspeuntner S, Ledig S, Kaufhold I, Hoellen F, Schiefer A Front Microbiol. 2019; 10:943.

PMID: 31134007 PMC: 6514060. DOI: 10.3389/fmicb.2019.00943.


Treatment Effectiveness of Azithromycin and Doxycycline in Uncomplicated Rectal and Vaginal Chlamydia trachomatis Infections in Women: A Multicenter Observational Study (FemCure).

Dukers-Muijrers N, Wolffs P, De Vries H, Gotz H, Heijman T, Bruisten S Clin Infect Dis. 2019; 69(11):1946-1954.

PMID: 30689759 PMC: 6853690. DOI: 10.1093/cid/ciz050.


Current Research of Chlamydial Infection Diseases in China.

Li X, Liang Q, Su G, Wu L, Lu X, Wang N Chin Med J (Engl). 2018; 131(4):486-489.

PMID: 29451157 PMC: 5830837. DOI: 10.4103/0366-6999.225063.


References
1.
Somani J, Bhullar V, Workowski K, Farshy C, Black C . Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis. 2000; 181(4):1421-7. DOI: 10.1086/315372. View

2.
Xia M, Suchland R, Carswell J, van Duzer J, Buxton D, Brown K . Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis. Antimicrob Agents Chemother. 2005; 49(9):3974-6. PMC: 1195391. DOI: 10.1128/AAC.49.9.3974-3976.2005. View

3.
Dean D, Suchland R, Stamm W . Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping. J Infect Dis. 2000; 182(3):909-16. DOI: 10.1086/315778. View

4.
Samra Z, Rosenberg S, Soffer Y, Dan M . In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis. 2001; 39(3):177-9. DOI: 10.1016/s0732-8893(01)00221-8. View

5.
Dreses-Werringloer U, Padubrin I, Zeidler H, Kohler L . Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. Antimicrob Agents Chemother. 2001; 45(11):3001-8. PMC: 90774. DOI: 10.1128/AAC.45.11.3001-3008.2001. View